Skip to main content

Table 5 Concentrations of anti-Hsp60 and anti-Hsp65 IgG antibodies in group of women with ovarian cancer depending on treatment phase and in control group

From: Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer

  Phase of antineoplastic treatment Controls
Untreated so far After chemotherapy n = 80
n = 72 n = 77
Anti-Hsp60 (AU/ml) 89,59 ± 89,99 99,91 ± 158,40 62,42 ± 33,93
(mean ± SD)
  % of positive results 28%* 19% 10%
  (> 90 percentile for control group) p = 0.0041 p = 0.1085
Anti-Hsp65 (AU/ml) 80,31 ± 86,71 109,64 ± 226,24 56,35 ± 35,57
(mean ± SD)
  % of positive results 19% 22%* 10%
  (> 90 percentile for control group) p = 0.1103 p = 0.0398
  1. *p < 0.05 in group of women with ovarian cancer compared to control group.